- Home
- BODI vs KPTI Comparison
BODI vs KPTI Comparison
Compare BODI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- KPTI
- Stock Information
- Founded
- BODI 1998
- KPTI 2008
- Country
- BODI United States
- KPTI United States
- Employees
- BODI N/A
- KPTI N/A
- Industry
- BODI Industrial Machinery/Components
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- BODI Industrials
- KPTI Health Care
- Exchange
- BODI Nasdaq
- KPTI Nasdaq
- Market Cap
- BODI 40.1M
- KPTI 44.5M
- IPO Year
- BODI N/A
- KPTI 2013
- Fundamental
- Price
- BODI $6.80
- KPTI $6.07
- Analyst Decision
- BODI Buy
- KPTI Buy
- Analyst Count
- BODI 2
- KPTI 6
- Target Price
- BODI $10.00
- KPTI $39.80
- AVG Volume (30 Days)
- BODI 14.7K
- KPTI 97.1K
- Earning Date
- BODI 11-11-2025
- KPTI 11-04-2025
- Dividend Yield
- BODI N/A
- KPTI N/A
- EPS Growth
- BODI N/A
- KPTI N/A
- EPS
- BODI N/A
- KPTI N/A
- Revenue
- BODI $324,871,000.00
- KPTI $137,269,000.00
- Revenue This Year
- BODI N/A
- KPTI $3.40
- Revenue Next Year
- BODI N/A
- KPTI $9.69
- P/E Ratio
- BODI N/A
- KPTI N/A
- Revenue Growth
- BODI N/A
- KPTI N/A
- 52 Week Low
- BODI $3.38
- KPTI $3.51
- 52 Week High
- BODI $8.71
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- BODI 67.83
- KPTI 50.63
- Support Level
- BODI $5.30
- KPTI $6.15
- Resistance Level
- BODI $7.29
- KPTI $6.85
- Average True Range (ATR)
- BODI 0.47
- KPTI 0.49
- MACD
- BODI 0.10
- KPTI -0.16
- Stochastic Oscillator
- BODI 77.42
- KPTI 21.93
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.